

# THE VEEDA NEWSLETTER



## Veeda Lifesciences had the honour of sponsoring EMN 2025

At EMN 2025, Athens, Veeda focused on reinforcing our commitment to driving innovation in hematological malignancies. Our scientists had the opportunity to present abstracts based on real world research.

[Read More](#)

### Inside Veeda Group: February 2025

From the CEO's Desk

Veeda Voice

Industry Insider

Employee Spotlight

 [info@veedalifesciences.com](mailto:info@veedalifesciences.com)

 [www.veedalifesciences.com](http://www.veedalifesciences.com)

 |  | 

Excellence  
In Everything

# From the CEO's DESK



## Reflections from EMN 2025 — Accelerating Impact in Myeloma Research

The 6th European Myeloma Network Meeting in Athens was more than a scientific gathering—it was a powerful reminder of how rapidly the myeloma research landscape is evolving. From discussions on AI-enabled trial design to emerging prognostic tools like MRD and mass spectrometry, the meeting reinforced that future-ready research demands not only data but deep cross-disciplinary collaboration.

What added depth to this experience was the calibre of dialogue our team engaged in with EMN leaders, investigators, and sponsors on how we collectively raise the bar in trial execution, data quality, and patient-centric outcomes. These were not just networking moments, but purposeful exchanges rooted in trust, shared ambition, and delivery credibility.

I'm proud of the team for representing Veeda Lifesciences as scientific partners who listen, contribute, and lead with integrity. EMN 2025 validated that our strength lies not just in our capabilities, but in our consistent ability to align science with execution, and our role in shaping tomorrow's standards in myeloma research.

Warm Regards,  
Dr. Mahesh Bhalgat  
Group CEO & MD, Veeda Lifesciences



[info@veedalifesciences.com](mailto:info@veedalifesciences.com)



[www.veedalifesciences.com](http://www.veedalifesciences.com)

## Analytical Sciences: Advancing Biopharma Characterization


### Driving Innovation at Veeda's Analytical Sciences Lab

Take a closer look at the specialized lab instruments used in Veeda's Analytical Sciences Lab ensuring each test supports safety, efficacy, and regulatory readiness.



### Leading the Future of Pharma at Ahmedabad Summit 2025

Veeda contributed to dynamic discussions at the Ahmedabad Pharma Summit 2025, emphasizing innovation, regulatory evolution, and collaboration for the future.



### GLP-1 RECEPTOR AGONISTS Bioequivalence Study of Semaglutide for Type 2 Diabetes Management


Evaluating Safety and Efficacy for Consistent Glycemic Control in Type 2 Diabetes Patients

#### Title

An open-label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period crossover bioequivalence study of Semaglutide, comparing the test and reference formulations in healthy adult subjects under fasting conditions.

### Semaglutide Study Reveals Advances in Biosimilarity

Veeda's Semaglutide case study highlights critical pharmacokinetic evaluations supporting advances in biosimilar drug development for diabetes care.



### Molecular Profiling of Denosumab: A Comprehensive Physicochemical and Structural Assessment

#### Type of Study

The study of the physicochemical properties and secondary structure of Denosumab involves a detailed analysis of its molecular composition and structural integrity. Physicochemical characterization focuses on evaluating the drug's molecular mass, disulphide linkages, glycoforms & N&C terminal sequence to ensure consistency & quality in its therapeutic performance. On the other hand, secondary structure characterization examines the arrangement of the protein's secondary structures, such as alpha-helices & beta-sheets, which are critical for its structural integrity and biological activity. Circular dichroism (CD) spectroscopy is employed to assess these structural features. This comprehensive study ensures the safety, efficacy & stability of Denosumab, supporting its use in clinical applications.

### Denosumab Research Boosts Osteoporosis Treatment Insights

Focused on bioequivalence and safety, Veeda's Denosumab study offers insights to strengthen treatment options for osteoporosis.







## Indian pharma to swiftly steer towards digital traceability to thwart counterfeit medicines

Indian pharma underscores the need to stand united, to innovate, and to reinforce public trust in medicine safety. There is a need to enhance transparency and responsiveness in safety reporting to drive ahead in the global market, said Chakravarthi AVPS, sr vice president (national), chairman - AP & Telangana, Federation of Pharma Entrepreneurs (FOPE).

[Read More](#)

## Sebela Pharma announces positive results from phase 3 TRIUMpH programme of tegoprazan in GERD

Braintree Laboratories, a part of Sebela Pharmaceuticals and a leading manufacturer of gastroenterology pharmaceutical products, announced positive topline results from two pivotal US phase 3 clinical trials evaluating tegoprazan, a novel potassium-competitive acid blocker (P-CAB), in patients with gastroesophageal reflux disease (GERD).

[Read More](#)

## Breakthrough in bowel cancer research will speed up diagnosis.

Patients could soon benefit from world-leading technology to diagnose bowel cancer earlier, faster and cheaper, reducing the need for invasive colonoscopies and biopsies, and potentially saving valuable time and resource for the NHS, the government has announced on Wednesday, 23rd April.

[Read More](#)

## Basilea Receives CHF 1.7 Million Milestone Payment from Asahi Kasei for Cresemba Sales in Japan

Basilea Pharmaceutica has earned a CHF 1.7 million milestone payment from Asahi Kasei Pharma following strong sales of its antifungal drug, Cresemba, in Japan. This marks the second consecutive quarterly milestone payment.

[Read More](#)

## Zealand Pharma Launches Phase 2b ZUPREME-2 Trial of Petrelintide for Obesity and Type 2 Diabetes

Zealand Pharma has enrolled the first participant in the ZUPREME-2 phase 2b trial, testing the efficacy and safety of once-weekly petrelintide in people with overweight or obesity and type 2 diabetes.

[Read More](#)




## Indian diabetic population on Human Mixtard concerned on changes in insulin therapy

India's diabetic population, particularly those on Novo Nordisk's Human Mixtard insulin, are now apprehensive regarding changes in prescription practices. These concerns are attributed to various factors including clinical efficacy, affordability, and accessibility.

[Read More](#)

## Health informatics and medical AI are making waves in job market

Indian hiring companies note that health informatics and medical AI are rapidly becoming two of the most promising career paths. Hospitals, startups, technology majors and even the government departments have created posts for informatics, medical AI roles as digital healthcare is indispensable.

[Read More](#)

## Indian pharma researchers are now focusing on monoclonal antibodies to treat malaria

Indian pharma researchers are now focusing on monoclonal antibodies to treat malaria. The current research is exploring new antimalarial drugs and strategies, including monoclonal antibodies, which show potential in preventing malaria infection.

[Read More](#)

Medicines & Healthcare products  
Regulatory Agency

## UK MHRA grants conditional marketing nod to Autolus Therapeutics' obecabtagene autoleucel to treat adults with relapsed or refractory B-cell precursor ALL

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine obecabtagene autoleucel (Aucatzyl), a chimeric antigen receptor (CAR) T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

[Read More](#)

INNOCARE

## China NMPA approves InnoCare Pharma's orelabrutinib for first-line treatment of patients with CLL/SLL

InnoCare Pharma announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL).

[Read More](#)

info@veedalifesciences.com



www.veedalifesciences.com

# Employee SPOTLIGHT

Reflections from EMN 2025



## James Brook COO ( Global Clinical Trials)


"At the EMN Conference, our team didn't just share our expertise—they made genuine connections. Their collaboration and energy created a sense of unity that resonated with everyone we met, leaving a lasting impression of our true commitment."

[Read More!](#)



## On the Ground in Athens

Dr. Mahesh Bhargat spent some great time with our Europe team in Athens- interacting, brainstorming, and sharing ideas. These face-to-face moments are key to building the strong teamwork that helps us move forward together.



## Spotlight on Clinical Research at EMN 2025

Veeda Lifesciences proudly presented the final Phase I/II BelaRd trial results, highlighting the combination of belamaf + Rd in intermediate-fit and frail NDMM patients.

[Read More!](#)



info@veedalifesciences.com



www.veedalifesciences.com



# Contact Us

## Address:

### Corporate Office

VEEDA CLINICAL RESEARCH LIMITED  
Satyamev House, Nr. Shalin Bungalow,  
Prahladnagar, Ahmedabad 380015

### Registered Office

Shivalik Plaza-A, Near IIM Ambawadi,  
Ahmedabad- 380015, Gujarat, India. CIN  
No. U73100GJ2004PTC044023

## Global Offices

- India
- Greece
- Italy
- Ireland



**Disclaimer:** "The information compiled and published in this newsletter has been sourced, collected and derived from various resources which are in the public domain available on the web & relevant sites. Veeda makes no claims, promises or guarantees about the accuracy, completeness, or adequacy of the contents of the newsletters & expressly disclaims liability for errors & omissions in the contents of this newsletter. The intent and object of this Newsletter is to only disseminate scientific information for knowledge up-gradation. The transmission or reproduction of any items covered in this newsletter beyond that allowed by fair use as defined in the copyright laws may require the written permission of the copyright owners, if any. Neither Veeda, nor its employees & contractors make any warranty, expressed or implied or statutory, including but not limited to the warranties of non-infringement of third party rights, title & the warranties of merchantability and fitness for a particular purpose with respect to content available from the newsletters. This is not a service by Veeda Clinical Research and it does not hold any responsibility for the accuracy of the news information provided herein."

 [info@veedalifesciences.com](mailto:info@veedalifesciences.com)

 [www.veedalifesciences.com](http://www.veedalifesciences.com)



**Excellence**  
**In Everything**